

Review Article

The Contentious Origins of SARS-CoV-2: A Comprehensive Review of Current Knowledge

Jose L Domingo¹

1. School of Medicine, Universitat Rovira i Virgili, Spain

The emergence of SARS-CoV-2 in late 2019 triggered a global pandemic (COVID-19) that has claimed millions of lives and continues to impact public health systems worldwide. This review examines current scientific evidence regarding the virus's origins, focusing on two primary hypotheses: zoonotic spillover and laboratory-related emergence. A comprehensive analysis of peer-reviewed literature primarily published between December 2023 and January 2025 was conducted, identifying relevant studies through searches of the PubMed and Scopus databases. Key earlier publications are also included to provide essential background and context. The analysis revealed strong phylogenetic evidence supporting a natural zoonotic origin, with several studies indicating close genetic relationships to bat coronaviruses. Environmental sampling data from the Huanan Seafood Market detected SARS-CoV-2 RNA in a high number of environmental samples from animal stalls. While the preponderance of evidence supports natural zoonotic spillover, the absence of a definitively identified intermediate host maintains some uncertainty. This review concludes with evidence-based recommendations for enhanced viral surveillance, implementation of One Health approaches, and strengthened international collaboration frameworks to prevent future coronavirus pandemics.

Corresponding author: Jose L Domingo, jose Luis.domingo@urv.cat

1. Introduction

The COVID-19 pandemic, caused by SARS-CoV-2, has dramatically reshaped global health systems and accelerated the pace of scientific research. While remarkable progress has been made in

understanding the virus, its transmission, and developing effective vaccines, significant knowledge gaps persist. These include the long-term health consequences of infection (long COVID or post-acute sequelae of SARS-CoV-2 infection)^{[1][2]}, the intricate mechanisms of immune evasion employed by evolving viral variants and their implications for vaccine efficacy and immune protection^{[3][4]}, the complex interplay of host factors and viral dynamics that contribute to severe disease outcomes (including the role of cytokine storms and other immunopathological processes)^{[5][6]}, the full spectrum of disease severity from asymptomatic infection to critical illness and the factors that influence this range^{[7][8]}, the cumulative effects of repeated or related infections on immune memory and long-term health^[9], the identification and characterization of animal reservoirs and the dynamics of spillover risk (including the potential for reverse zoonosis)^{[10][11]}, the emergence and spread of antiviral resistance mutations and the need for new therapeutic targets^{[12][13]}, the influence of environmental factors^{[14][15]}, and the broader socio-economic impacts of the pandemic extending beyond acute illness^[16], among others. Addressing these multifaceted challenges is essential not only for improving current disease management but also for strengthening global pandemic preparedness and building more resilient public health systems^[17].

A particularly crucial (yet still unresolved) question concerns the origin of SARS-CoV-2. The COVID-19 pandemic triggered an unprecedented surge in scientific research, dwarfing previous efforts in the medical sciences. Table 1 presents a comparative analysis of citation counts (as of January 31, 2025) in the databases PubMed and Scopus for research related to COVID-19 and SARS-CoV-2, juxtaposed with citation counts for cancer, Alzheimer's disease (AD), and influenza/flu, diseases with significantly longer histories of scientific investigation. This comparison highlights the explosive growth of COVID-19 and SARS-CoV-2 research within a remarkably short five-year timeframe. Even in the early stages of the pandemic, as of July 2020, the volume of COVID-19 and SARS-CoV-2 related publications was already substantial. PubMed contained 279,690 entries for COVID-19 and 170,591 for SARS-CoV-2, while Scopus listed 343,925 and 153,183, respectively^[18]. In contrast, influenza research, after decades of study, yielded considerably fewer entries (PubMed: 157,209; Scopus: 199,484). Despite this massive research mobilization, investigations specifically focused on the origin of SARS-CoV-2 remain comparatively underrepresented in the literature (Table 1), underscoring the persistent challenge of uncovering the origins of that coronavirus.

Search term in the databases	PubMed	Scopus
COVID-19	464,052	664,068
SARS-CoV-2	247,139	255,474
Origin of SARS-CoV-2	3,872	3,046
Cancer (human)	4,403,838	3,535,707
Alzheimer's disease	227,245	307,486
Influenza	165,647	240,307
Flu	91,549	43,531

Table 1. Number of results retrieved from PubMed and Scopus (January 21, 2025) for the specified topics

This review is the latest in a series of analyses dedicated to examining the evolving body of evidence surrounding the origin of SARS-CoV-2. In previous publications^{[18][19][20]}, the ongoing debate between the two primary hypotheses: natural zoonotic spillover from an animal reservoir to humans and a laboratory-related event, has been documented. These earlier reviews highlighted the lack of definitive evidence supporting either hypothesis, emphasizing the need for rigorous, transparent, and collaborative research. While phylogenetic analyses and other data suggested a natural origin, potentially involving bat coronaviruses, the absence of a definitively identified intermediate host and other inconsistencies in early epidemiological data have fueled ongoing discussion and debate.

2. Search strategy

The current review synthesizes the peer-reviewed scientific literature primarily published between December 1, 2023, and January 31, 2025, identified through comprehensive searches of the databases PubMed and Scopus. The "origin of SARS-CoV-2" was again the search term. To maintain methodological rigor and focus on empirical evidence, non-peer-reviewed material, opinion pieces, and studies lacking original data were excluded from the analysis.

To ensure transparency and reproducibility, the following inclusion and exclusion criteria were applied.

Inclusion criteria: studies were included if their primary focus was on the origin of SARS-CoV-2, addressing either the zoonotic spillover hypothesis, the laboratory-related emergence hypothesis, or related aspects (e.g., reverse zoonosis, animal reservoirs, phylogenetic analyses directly relevant to origin). *Original Data:* studies were included if they presented original empirical data (genomic sequences, epidemiological data, environmental sampling results, experimental findings). Purely theoretical or opinion pieces were excluded. *Peer-Reviewed:* studies were included if published in a peer-reviewed scientific journal. Preprints were excluded., being studies published in English prioritized.

Exclusion Criteria: studies not primarily focused on the origin of SARS-CoV-2, those lacking original empirical data (e.g., reviews without new data, editorials, commentaries), non-peer-reviewed publications (preprints, conference abstracts, grey literature) and studies not available in the English language.

Search term: "origin of SARS-CoV-2" was used in PubMed and Scopus. The primary search focused on publications between December 1, 2023, and January 31, 2025. However, key earlier publications were also included for context. No specific impact factor cutoff was used. Relevance and methodological rigor were prioritized.

3. Zoonotic origin of SARS-CoV-2, the dominant narrative: Recent evidence

The predominant scientific consensus strongly favors a zoonotic origin for SARS-CoV-2^{[21][20][22][23][24][25][26][27][28]}. This hypothesis posits that the virus jumped from an animal reservoir to humans, a process known as zoonotic spillover. Several converging lines of evidence support this theory. Firstly, the phylogenetic analyses and genomic similarities. Recent extensive phylogenetic analyses provide strong evidence for a natural zoonotic origin^{[23][24][25][26][27][28]}. By “strong phylogenetic evidence”, I refer to a convergence of multiple, independently derived phylogenetic analyses that consistently place SARS-CoV-2 within a clade of bat coronaviruses, particularly those from *Rhinolophus bats*, with high statistical support. This strength is based on: 1) Consistency Across Studies: Multiple research groups, using different datasets and phylogenetic methods, have arrived at similar conclusions

regarding the close evolutionary relationship between SARS-CoV-2 and bat coronaviruses^{[29][30]}, 2) High Bootstrap/Posterior Probability Values: The relevant branches in the phylogenetic trees (linking SARS-CoV-2 to bat coronaviruses) typically exhibit high bootstrap support values (e.g., >70%) or posterior probabilities (e.g., >0.95), indicating strong statistical confidence in the inferred relationships, 3) Identification of Key Genomic Features: Phylogenetic analyses are supported by identifying specific, shared genomic features between SARS-CoV-2 and related bat coronaviruses, such as receptor-binding domain (RBD) motifs and other conserved regions, and 4) Outgroup Comparison: Including appropriate outgroup sequences (e.g., coronaviruses from other animal species) helps root the trees and confirm the direction of evolutionary relationships. While phylogenies represent hypotheses about evolutionary relationships, the consistent findings across multiple studies, strong statistical support, and shared genomic features provide compelling evidence for a zoonotic origin

On the other hand, an epidemiological link to the Huanan seafood market was demonstrated. Thus, epidemiological investigations traced many early COVID-19 cases to the Huanan Seafood Wholesale Market in Wuhan, China^{[31][32][33]}. The detection of SARS-CoV-2 RNA and animal DNA in environmental samples collected from the market after its closure further strengthens this association^[34]. Finally, the historical precedent of zoonotic coronavirus outbreaks, such as *Severe Acute Respiratory Syndrome* (SARS) and *Middle East Respiratory Syndrome* (MERS)^{[35][36][37]}, also originated from zoonotic transmission, established a clear precedent for coronaviruses to cross species barriers and infect humans^{[23][38]}.

Adding complexity to the zoonotic narrative is the discovery of related Sarbecoviruses in bats. As cited above, Chen S et al.^[29] identified BANAL-20-52, Rp22DB159, and S18CXBatR24 as close relatives of SARS-CoV-2, detecting seven out of nine key genomic features of SARS-CoV-2 in these viruses from Laos, Vietnam, and China. Interestingly, they identified RC1, a segment of the NSP3 protein, in BANAL-20-52, representing a second crucial clue for tracing SARS-CoV-2's origin. While RCo, encoding the furin cleavage site, remains undetected outside SARS-CoV-2, the detection of eight out of nine wild-type features in viruses from Laos offers a significant lead in the search for the progenitor virus. The furin cleavage site itself, a unique feature of SARS-CoV-2, has been a point of contention, with some suggesting it points towards artificial manipulation. However, the presence of other key genomic features in related bat coronaviruses suggests that this site could have arisen through natural evolutionary processes.

Despite the compelling evidence for a zoonotic origin, the precise intermediate host that facilitated the spillover from bats to humans remains to be definitively identified. Ongoing research efforts are focused on identifying this missing link. It's important to acknowledge that the absence of a confirmed intermediate host could be attributed to several factors. 1) limited sampling: surveillance in wildlife, especially in relevant regions, may not have been extensive enough, 2) rapid viral evolution: the coronavirus may have evolved rapidly in the intermediate host, obscuring the lineage, 3) extinct or unsampled host: the intermediate host might be rare, geographically restricted, or even extinct, and 4) limited sample access: access to relevant animal samples and biorepositories may be restricted. Furthermore, the possibility of direct transmission from bats to humans, without an intermediate host, should be considered. While less common for some coronaviruses, direct transmission is not impossible, particularly with close human-bat contact. The absence of a confirmed intermediate host, while a significant knowledge gap, does not negate the substantial evidence supporting a zoonotic origin.

4. Recent developments on the laboratory leak hypothesis

Despite the robust evidence supporting a zoonotic origin, the hypothesis of a laboratory leak, either accidental or intentional, has gained traction, particularly in public discourse. This hypothesis suggests that SARS-CoV-2 might have originated from research conducted on coronaviruses in a laboratory, potentially the Wuhan Institute of Virology (WIV). However, this hypothesis is primarily based on circumstantial evidence, speculation, and misinformation, and lacks direct scientific support. Thus, currently, the absence of direct evidence remains. Proponents of the lab leak hypothesis have not presented any concrete scientific evidence to substantiate their claims^{[23][39]}, while investigations into the WIV's work have not revealed any evidence of improper handling or release of the virus. Moreover, the genetic analysis is consistent with natural evolution. In relation to this, detailed genetic analysis of SARS-CoV-2 has not revealed signs of artificial manipulation or genetic engineering. The genome of SARS-CoV-2 exhibits the natural evolutionary changes expected in a coronavirus^{[26][28]}. On the other hand, risk assessment tools, such as the modified Grunow-Finke assessment tool (mGFT), have been applied to assess the likelihood of a natural versus unnatural origin of SARS-CoV-2. While some studies using these tools have suggested a higher likelihood of an unnatural origin^[40], these assessments rely on subjective criteria and expert opinion. However, it is important to maintain scientific openness and acknowledge that the possibility of a lab leak cannot be

categorically excluded^{[41][40]}, although the overwhelming weight of scientific evidence strongly favors a natural zoonotic origin^{[23][39]}.

5. Reverse zoonosis: An increasing concern

Another critical aspect of SARS-CoV-2's transmission dynamics is reverse zoonosis, where humans transmit the virus to animals^{[42][43]}. This has been observed in a variety of animal species, raising concerns about the establishment of animal reservoirs and the potential for future spillback into human populations. Cases of SARS-CoV-2 transmission from humans to domestic animals, such as cats and dogs, as well as wild animals, including mink and zoo animals, have been documented. This highlights the coronavirus's ability to infect a broad range of hosts and the potential for establishing new animal reservoirs^[42]. Thus, the establishment of animal reservoirs could complicate efforts to control the coronavirus and pose risks to wildlife conservation. Monitoring and mitigating reverse zoonosis are crucial for the long-term control of SARS-CoV-2 and preventing future outbreaks.

6. Scientific inquiry and transparency

The ongoing debate surrounding SARS-CoV-2's origin underscores the critical importance of open scientific inquiry, transparency, and international collaboration^[44]. Conclusions must be grounded in robust scientific evidence and subjected to rigorous scrutiny. The politicization of the origin debate significantly undermines public trust in science and impedes efforts to effectively address the pandemic^{[45][39]}. The spread of misinformation and conspiracy theories about the origin of SARS-CoV-2 has created significant challenges for public health communication and scientific discourse^[46]^[47]. Addressing these challenges requires clear, evidence-based communication and efforts to build public trust in science^[48]. As Zaidi and Singh^[49], have emphasized, a thorough understanding of COVID-19's epidemiology, including comparisons with other coronaviruses and its evolutionary trajectory, is essential for developing effective public health interventions. Effective investigation of the origin of SARS-CoV-2 requires international collaboration and data sharing, which includes cooperation between scientists, public health authorities, and governments to ensure comprehensive and unbiased research.

7. One Health and pandemic preparedness

Holmes^[23] strongly argued for a natural zoonotic emergence tied to the Huanan Market, emphasizing the lack of direct evidence supporting a laboratory origin. He highlights the coronavirus's subsequent adaptation to humans, marked by increasing transmissibility and virulence, culminating in the emergence of the Omicron variant. He also remarked on the frequent human-to-animal transmission, classifying SARS-CoV-2 as a highly host-generalist virus. This author has stressed the importance of learning from the SARS-CoV-2 origin story to prevent future zoonotic pandemics, emphasizing that without such lessons, further outbreaks are inevitable. He also suggests that focusing on understanding the mechanisms of zoonotic spillover and improving surveillance in animal populations are crucial for preventing future pandemics^[23].

The COVID-19 pandemic has underscored the crucial role of the "One Health" approach in managing zoonotic threats^{[50][51]}. This approach recognizes the interconnectedness of human, animal, and environmental health, emphasizing the need for collaborative efforts to prevent and prepare for future pandemics. Huang et al.^[50] advocate for vigilant surveillance programs at the interfaces between wildlife, livestock, and humans as the most effective strategy for mitigating the risk of zoonotic spillovers. This includes strengthening surveillance in animal populations, particularly those in close contact with humans, and improving our understanding of the complex interactions that drive viral emergence.

8. Conclusions and recommendations

The debate surrounding SARS-CoV-2's origin highlights the complexities of scientific inquiry and the challenges of communicating scientific findings to the public. As Gostin and Gronvall^[44] point out, origins investigations are scientific endeavors that require time, access to key sites, open scientific exchange, and transparency. While these investigations may proceed slower than the news cycle, they are essential for unraveling the mysteries of emerging infectious diseases and preparing for future outbreaks. The controversy surrounding SARS-CoV-2's origin serves as a stark reminder of the need for robust scientific practices, transparent communication, and international collaboration to effectively address global health threats.

While the overwhelming weight of scientific evidence leans towards a natural zoonotic origin for SARS-CoV-2 (Table 2), the lack of a definitively identified intermediate host, *and the* limitations in

accessing all potentially relevant data, particularly from research facilities, highlight the need for continued, targeted investigation. The complexities of viral evolution and the challenges of tracing a virus's origins underscore the importance of open scientific discourse and transparency. Crucially, further research must be driven by specific, evidence-based questions and the pursuit of verifiable data, not by unsubstantiated speculation. The goal is to address remaining scientific uncertainties based on incomplete information, not to pursue claims lacking empirical support. Full transparency and data sharing, including access to laboratory records and samples where relevant, are paramount to definitively resolving the question of SARS-CoV-2's origins.

Based on the above, as well as on the information collected from previous reports and studies on the origin of SARS-CoV-2, the following recommendations are suggested: 1) Strengthen surveillance programs in wild animal populations, particularly those in close contact with humans, to identify potential reservoirs and intermediate hosts of emerging coronaviruses, 2) promote full transparency and open communication in research activities related to potentially dangerous pathogens such as coronaviruses, 3) implement a comprehensive One Health approach that integrates human, animal, and environmental health considerations, 4) develop and refine risk assessment tools to evaluate the potential for both natural and unnatural origins of emerging infectious diseases, 5) improve communication of scientific findings to the public, ensuring that complex information is presented in a clear and accessible way, and 6) foster international collaboration in research and surveillance efforts related to emerging infectious diseases.

Topic	Key Findings	References
Zoonotic Origin	Phylogenetic analyses confirm strong genomic similarities between SARS-CoV-2 and bat coronaviruses, particularly in <i>Rhinolophus</i> bats. Related coronaviruses have also been identified in pangolins.	Holmes ^[23] ; Samson et al. ^[27] ; Wang ^[28]
Huanan Market Link	Epidemiological and environmental sampling data reinforce the association between early COVID-19 cases and the Huanan Seafood Market in Wuhan. The presence of SARS-CoV-2 RNA and animal DNA in samples supports zoonotic spillover.	Liu et al. ^[32] ; Crits-Christoph et al. ^[34] ; Mallapaty ^[33]
Intermediate Host	While no definitive intermediate host has been identified, recent studies suggest potential reservoirs, including small mammals traded in wet markets.	Chen S et al. ^[29]
Reverse Zoonosis	SARS-CoV-2 has been found in domestic and wild animals, raising concerns about animal reservoirs and potential spillback into human populations.	Milich and Morse ^[42] ; Qiu et al. ^[43]
Laboratory Leak Hypothesis	No direct evidence supports a lab leak; genetic analysis does not indicate artificial manipulation. Some studies using risk assessment tools suggest an unnatural origin, but these rely on subjective criteria.	Holmes ^[23] ; Alwine et al. ^[41] ; Chen X et al. ^[40]
One Health Approach	Calls for enhanced surveillance at human-animal interfaces, improved pandemic preparedness, and international collaboration in viral research.	Huang et al. ^[50] ; Holmes ^[23]

Table 2. Summary of key recent findings on the origin and evolution of SARS-CoV-2

Based on the above, as well as on the information collected from previous reports and studies on the origin of SARS-CoV-2, the following recommendations are suggested: 1) strengthen surveillance programs in wild animal populations, particularly those in close contact with humans, to identify potential reservoirs and intermediate hosts of emerging coronaviruses, which should include serological surveys, viral sequencing, and ecological studies to understand the factors driving viral

spillover, 2) promote transparency and open communication in research activities related to potentially dangerous pathogens such as coronaviruses, which includes sharing data, protocols, and findings in a timely and accessible manner. International collaboration and data sharing are crucial for advancing our understanding of viral emergence, 3) implement a comprehensive One Health approach that integrates human, animal, and environmental health considerations, which requires collaboration among diverse disciplines, including virology, ecology, veterinary medicine, and public health, 4) develop and refine risk assessment tools to evaluate the potential for both natural and unnatural origins of emerging infectious diseases, which should include assessing the risks associated with laboratory research on potentially dangerous pathogens and implementing appropriate biosafety and biosecurity measures, 5) improve communication of scientific findings to the public, ensuring that complex information is presented in a clear and accessible way, which should include addressing public concerns and misconceptions about scientific research and fostering trust in the scientific process, and 6) foster international collaboration in research and surveillance efforts related to emerging infectious diseases, which includes sharing resources, expertise, and data to accelerate the understanding of viral emergence and improve the ability to respond to potential future pandemics.

Statements and Declarations

Conflicts of interest

The author declares that he has no conflicts of interest (COIs).

References

1. [△]Parums DV. *Long COVID or Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and the Urgent Need to Identify Diagnostic Biomarkers and Risk Factors.* *Med Sci Monit.* 2024 Sep 18;30:e946512. doi:10.12659/MSM.946512.
2. [△]Basaca DG, Jugănaru I, Belei O, Nicoară DM, Asproni R, Stoicescu ER, Mărginean O. *"Long COVID in Children and Adolescents: Mechanisms, Symptoms, and Long-Term Impact on Health—A Comprehensive Review."* *J Clin Med.* 2025 Jan 9;14(2):378. doi:10.3390/jcm14020378.
3. [△]Angius F, Puxeddu S, Zaimi S, Canton S, Nematollahzadeh S, Pibiri A, Delogu I, Alvisi G, Moi ML, Manz in A. *"SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development."* *Vaccines (Basel).* 2024 Dec 28;13(1):17. doi:10.3390/vaccines13010017.

4. [△]Shi NDJ, Marcato AJ, Spirkoska V, Meagher N, Villanueva-Cabezas JP, Price DJ. The Asymptomatic Proportion of SARS-CoV-2 Omicron Variant Infections in Households: A Systematic Review. *Influenza Other Respir Viruses*. 2024 Jul;18(7):e13348. doi:10.1111/irv.13348.
5. [△]Attiq A, Afzal S, Wahab HA, Ahmad W, Kandeel M, Almofti YA, Alameen AO, Wu YS. "Cytokine Storm-Induced Thyroid Dysfunction in COVID-19: Insights into Pathogenesis and Therapeutic Approaches." *Drug Des Devel Ther*. 2024 Sep 20;18:4215-4240. doi:10.2147/DDDT.S475005.
6. [△]Gutierrez-Chavez C, Aperrigue-Lira S, Ortiz-Saavedra B, Paz I. "Chemokine receptors in COVID-19 infection." *Int Rev Cell Mol Biol*. 2024;388:53-94. doi:10.1016/bs.ircmb.2024.05.002.
7. [△]Raval C, Rheingold SZ, Gordon AM, Hardigan P. Zinc Deficiency Associated With an Increase in Mortality in COVID-19 Patients: A Meta-Analysis. *Cureus*. 2025 Jan 6;17(1):e77011. doi:10.7759/cureus.77011.
8. [△]Yang JM, Li ZQ, Zhong YB, Xie HY, Luo Y, Xiao L, Liao JH, Wang MY. Association Between Vitamin D and COVID-19-Related Outcomes: An Umbrella Review of Meta-Analyses. *Nutr Rev*. 2025 Feb 5:nuae225. doi:10.1093/nutrit/nuae225.
9. [△]Kikinis Z, Castañeyra-Perdomo A, González-Mora JL, Rushmore RJ, Toppa PH, Haggerty K, Papadimitriou G, Rathi Y, Kubicki M, Kikinis R, Heller C, Yeterian E, Besteher B, Pallanti S, Makris N. "Investigating the structural network underlying brain-immune interactions using combined histopathology and neuroimaging: a critical review for its relevance in acute and long COVID-19." *Front Psychiatry*. 2024 Mar 25;15:1337888. doi:10.3389/fpsyt.2024.1337888.
10. [△]Faraji N, Zeinali T, Joukar F, Aleali MS, Eslami N, Shenagari M, Mansour-Ghanaei F. "Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies." *Heliyon*. 2024 Apr 25;10(9):e30208. doi:10.1016/j.heliyon.2024.e30208.
11. [△]Wang D, Li L, Ren Z, Yu Y, Zhang Z, Zhou J, Zhao H, Zhao Z, Shi P, Mi X, Jin X, Deng Z, Li J, Chen J. Host Specificity and Geographic Dispersion Shape Virome Diversity in Rhinolophus Bats. *Mol Ecol*. 2025 Feb;34(4):e17645. doi:10.1111/mec.17645.
12. [△]Batool S, Chokkakula S, Jeong JH, Baek YH, Song MS. "SARS-CoV-2 drug resistance and therapeutic approaches." *Heliyon*. 2025 Jan 15;11(2):e41980. doi:10.1016/j.heliyon.2025.e41980.
13. [△]Meybodi SM, Rabori VS, Salkhorde D, Jafari N, Zeinaly M, Mojodi E, Kesharwani P, Saberiyan M, Sahebkar A. Dexamethasone in COVID-19 treatment: Analyzing monotherapy and combination therapy approaches. *Cytokine*. 2024 Dec;184:156794. doi:10.1016/j.cyto.2024.156794.
14. [△]Domingo JL, Marquès M, Rovira J. "Influence of airborne transmission of SARS-CoV-2 on COVID-19 pandemic. A review." *Environ Res*. 2020 Sep;188:109861. doi:10.1016/j.envres.2020.109861.

15. [△]Núñez-Delgado A, Ahmed W, Bontempi E, Domingo JL. The environment, epidemics, and human health. *Environ Res.* 2022 Nov;214(Pt 2):113931. doi:10.1016/j.envres.2022.113931.
16. [△]GBD 2021 Demographics Collaborators. "Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021." *Lancet.* 2024 May 18;403(10440):1989-2056. doi:10.1016/S0140-6736(24)00476-8.
17. [△]Perlman S, Peiris M. Coronavirus research: knowledge gaps and research priorities. *Nat Rev Microbiol.* 2023 Mar;21(3):125-126. doi:10.1038/s41579-022-00837-3
18. ^{a, b}Domingo JL. "What we know and what we need to know about the origin of SARS-CoV-2." *Environ Res.* 2021 Sep;200:111785. doi:10.1016/j.envres.2021.
19. [△]Domingo JL. "An updated review of the scientific literature on the origin of SARS-CoV-2." *Environ Res.* 2022 Dec;215(Pt 1):114131. doi:10.1016/j.envres.2022.114131.
20. ^{a, b}Domingo JL. "Four Years Later, Is It Already Known The Origin Of SARS-Cov-2?." *J Comm Med and Pub Health Rep.* 2024 5(02). Doi: 10.38207/JCMPHR/2024/JAN05020519.
21. [△]Barbari A. "A Different Perspective on the COVID-19 Pandemic: Origin of the Outbreak (Part 1)." *Exp Cl in Transplant.* 2024 Jan;22(Suppl 2):1-14. doi:10.6002/ect.2023.0074.
22. [△]Holmes EC, Goldstein SA, Rasmussen AL, Robertson DL, Crits-Christoph A, Wertheim JO, Anthony SJ, Barclay WS, Boni MF, Doherty PC, Farrar J, Geoghegan JL, Jiang X, Leibowitz JL, Neil SJD, Skern T, Weiss SR, Worobey M, Andersen KG, Garry RF, Rambaut A. "The origins of SARS-CoV-2: A critical review." *Cell.* 2021 Sep 16;184(19):4848-4856. doi:10.1016/j.cell.2021.08.017.
23. ^{a, b, c, d, e, f, g, h, i, j}Holmes EC. "The Emergence and Evolution of SARS-CoV-2." *Annu Rev Virol.* 2024 Sep;11(1):21-42. doi:10.1146/annurev-virology-093022-013037.
24. ^{a, b}Latinne A, Hu B, Olival KJ, Zhu G, Zhang LB, Li H, Chmura AA, Field HE, Zambrana-Torrel C, Epstein JH, Li B, Zhang W, Wang LF, Shi ZL, Daszak P. "Origin and cross-species transmission of bat coronavirus in China." *Nat Commun.* 2024 Dec 19;15(1):10705. doi:10.1038/s41467-024-55384-7.
25. ^{a, b}Thakur N, Das S, Kumar S, Maurya VK, Dhama K, Paweska JT, Abdel-Moneim AS, Jain A, Tripathi AK, Puri B, Saxena SK. Tracing the origin of Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A systematic review and narrative synthesis. *J Med Virol.* 2022 Dec;94(12):5766-5779. doi:10.1002/jmv.28060.
26. ^{a, b, c}Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, Katzourakis A. The evolution of SARS-CoV-2. *Nat Rev Microbiol.* 2023 Jun;21(6):361-379. doi:10.1038/s41579-023-00878-2.

27. ^{a, b, c}Samson S, Lord É, Makarenkov V. Assessing the emergence time of SARS-CoV-2 zoonotic spillover. *PLoS One*. 2024 Apr 4;19(4):e0301195. doi:10.1371/journal.pone.0301195.
28. ^{a, b, c, d}Wang A. Integrating Fréchet distance and AI reveals the evolutionary trajectory and origin of SARS-CoV-2. *J Med Virol*. 2024 Mar;96(3):e29557. doi:10.1002/jmv.29557.
29. ^{a, b, c}Chen S, Ruan C, Guo Y, Chang J, Yan H, Chen L, Duan Y, Duan G, Bei J, Li X, Gao S. "Emergence of crucial evidence catalyzing the origin tracing of SARS-CoV-2." *PLoS One*. 2024 Aug 30;19(8):e0309557. doi:10.1371/journal.pone.0309557.
30. ^ΔJacob Machado D, Scott R, Guirales S, Janies DA. Fundamental evolution of all Orthocoronavirinae including three deadly lineages descendent from Chiroptera-hosted coronaviruses: SARS-CoV, MERS-CoV and SARS-CoV-2. *Cladistics*. 2021 Oct;37(5):461-488. doi:10.1111/cla.12454.
31. ^ΔLewis D, Kozlov M, Lenharo M. "COVID-origins data from Wuhan market published: what scientists think." *Nature*. 2023 Apr;616(7956):225-226. doi:10.1038/d41586-023-00998-y.
32. ^{a, b}Liu WJ, Liu P, Lei W, Jia Z, He X, Shi W, Tan Y, Zou S, Wong G, Wang J, Wang F, Wang G, Qin K, Gao R, Zhang J, Li M, Xiao W, Guo Y, Xu Z, Zhao Y, Song J, Zhang J, Zhen W, Zhou W, Ye B, Song J, Yang M, Zhou W, Dai Y, Lu G, Bi Y, Tan W, Han J, Gao GF, Wu G. Surveillance of SARS-CoV-2 at the Huanan Seafood Market. *Nature*. 2024 Jul;631(8020):402-408. doi:10.1038/s41586-023-06043-2.
33. ^{a, b}Mallapaty S. COVID pandemic started in Wuhan market animals after all, suggests latest study. *Nature*. 2024 Oct;634(8032):14-15. doi:10.1038/d41586-024-03026-9.
34. ^{a, b}Crits-Christoph A, Levy JI, Pekar JE, Goldstein SA, Singh R, Hensel Z, Gangavarapu K, Rogers MB, Moshiri N, Garry RF, Holmes EC, Koopmans MPG, Lemey P, Peacock TP, Popescu S, Rambaut A, Robertson DL, Suchard MA, Wertheim JO, Rasmussen AL, Andersen KG, Worobey M, Débarre F. "Genetic tracing of market wildlife and viruses at the epicenter of the COVID-19 pandemic." *Cell*. 2024 Sep 19;187(19):5468-5482.e11. doi:10.1016/j.cell.2024.08.010.
35. ^ΔAmeni G, Zewude A, Tulu B, Derara M, Bayissa B, Mohammed T, Degefa BA, Hamad ME, Tibbo M, Bariyye R. "A Narrative Review on the Pandemic Zoonotic RNA Virus Infections Occurred During the Last 25 Years." *J Epidemiol Glob Health*. 2024 Dec;14(4):1397-1412. doi:10.1007/s44197-024-00304-7.
36. ^ΔCui J, Li F, Shi ZL. "Origin and evolution of pathogenic coronaviruses." *Nat Rev Microbiol*. 2019 Mar;17(3):181-192. doi:10.1038/s41579-018-0118-9.
37. ^ΔKesheh MM, Hosseini P, Soltani S, Zandi M. "An overview on the seven pathogenic human coronaviruses." *Rev Med Virol*. 2022 Mar;32(2):e2282. doi:10.1002/rmv.2282.

38. [△]Pagani I, Ghezzi S, Alberti S, Poli G, Vicenzi E. Origin and evolution of SARS-CoV-2. *Eur Phys J Plus*. 2023;138(2):157. doi:10.1140/epjp/s13360-023-03719-6.
39. [△], [△], [△]The Lancet Microbe. COVID-19 origins: plain speaking is overdue. *Lancet Microbe*. 2024 Aug;5(8):100953. doi:10.1016/j.lanmic.2024.07.016.
40. [△], [△], [△]Chen X, Kalyar F, Chughtai AA, MacIntyre CR. "Use of a risk assessment tool to determine the origin of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)." *Risk Anal*. 2024 Aug;44(8):1896-1906. doi:10.1111/risa.14291.
41. [△], [△]Alwine JC, Casadevall A, Enquist LW, Goodrum FD, Imperiale MJ. "A Critical Analysis of the Evidence for the SARS-CoV-2 Origin Hypotheses." *J Virol*. 2023 Apr 27;97(4):e0036523. doi:10.1128/jvi.00365-23.
42. [△], [△], [△]Milich KM, Morse SS. The reverse zoonotic potential of SARS-CoV-2. *Heliyon*. 2024 Jun 13;10(12):e33040. doi:10.1016/j.heliyon.2024.e33040.
43. [△], [△]Qiu X, Liu Y, Sha A. SARS-CoV-2 and natural infection in animals. *J Med Virol*. 2023 Jan;95(1):e28147. doi:10.1002/jmv.28147.
44. [△], [△]Gostin LO, Gronvall GK. "The Origins of Covid-19 - Why It Matters (and Why It Doesn't)." *N Engl J Med*. 2023 Jun 22;388(25):2305-2308. doi:10.1056/NEJMp2305081.
45. [△]Alwine J, Goodrum F, Banfield B, Bloom D, Britt WJ, Broadbent AJ, et al. (2024). The harms of promoting the lab leak hypothesis for SARS-CoV-2 origins without evidence. *J Virol*. 98(9):e0124024. doi: 10.1128/jvi.01240-24.
46. [△]Kbaier D, Kane A, McJury M, Kenny I. "Prevalence of Health Misinformation on Social Media—Challenges and Mitigation Before, During, and Beyond the COVID-19 Pandemic: Scoping Literature Review." *J Med Internet Res*. 2024 Aug 19;26:e38786. doi:10.2196/38786.
47. [△]Kisa S, Kisa A. "A Comprehensive Analysis of COVID-19 Misinformation, Public Health Impacts, and Communication Strategies: Scoping Review." *J Med Internet Res*. 2024 Aug 21;26:e56931. doi:10.2196/56931.
48. [△]Lee SJ, Lee CJ, Hwang H. "The impact of COVID-19 misinformation and trust in institutions on preventive behaviors." *Health Educ Res*. 2023 Jan 20;38(1):95-105. doi:10.1093/her/cyaco38.
49. [△]Zaidi AK, Singh RB. Epidemiology of COVID-19. *Prog Mol Biol Transl Sci*. 2024;202:25-38. doi:10.1016/bs.pmbts.2023.09.002.
50. [△], [△], [△]Huang CY, Su SB, Chen KT. "Surveillance strategies for SARS-CoV-2 infections through one health approach." *Heliyon*. 2024 Aug 30;10(17):e37128. doi:10.1016/j.heliyon.2024.e37128.

51. [△]Shehata AA, Attia YA, Rahman MT, Basiouni S, El-Seedi HR, Azhar EI, Khafaga AF, Hafez HM. Diversity of Coronaviruses with Particular Attention to the Interspecies Transmission of SARS-CoV-2. *Animals (Basel)*. 2022 Feb 4;12(3):378. doi:10.3390/ani12030378.

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.